By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) –Evotec today said that it has teamed up with PsychoGenics to offer pharmaceutical and biotech companies CNS drug discovery services.

The firms will offer clients access to their complementary drug discovery platforms for identifying and developing new therapeutics for central nervous system disorders. Financial and other terms of the agreement were not disclosed.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.